# Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo

## TL;DR

This study compares asthma flare-ups in patients on mepolizumab and placebo, finding differences in lung function and recovery.

## Contribution

The study provides new insights into the nature of asthma exacerbations during mepolizumab treatment.

## Key findings

- Mepolizumab-treated exacerbations show less peak expiratory flow reduction compared to placebo.
- Symptom scores are similar between mepolizumab and placebo groups during exacerbations.
- Symptoms recover more slowly in mepolizumab-treated patients, suggesting less prednisolone responsiveness.

## Abstract

Mepolizumab, a monoclonal antibody targeting interleukin (IL)-5, depletes circulating eosinophils and reduces exacerbations of severe eosinophilic asthma [1]. However, some people continue to exacerbate potentially due to different, less corticosteroid-responsive mechanisms [2]. To characterise the changes in symptom and lung function seen in on-biologic exacerbations, we conducted a post hoc comparison of diary card data from prednisolone-treated exacerbations occurring during treatment with mepolizumab or placebo in three placebo-controlled trials [1, 3, 4].

Asthma exacerbations in people treated with mepolizumab result in less peak expiratory flow reduction than placebo but similar symptom scores. Symptoms recover slower, indicating these exacerbations may be less prednisolone responsive.
https://bit.ly/3xQsFRB